Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma

S. Fuji, H. Fujiwara, N. Nakano, A. Wake, Y. Inoue, T. Fukuda, M. Hidaka, Y. Moriuchi, Toshihiro Miyamoto, N. Uike, J. Taguchi, T. Eto, T. Tomoyose, T. Kondo, A. Yamanoha, T. Ichinohe, Y. Atsuta, A. Utsunomiya

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, <100 days, n=72; late transplant group, ≥100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3% vs 31.2%). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.

Original languageEnglish
Pages (from-to)205-211
Number of pages7
JournalBone Marrow Transplantation
Volume51
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Adult T Cell Leukemia Lymphoma
Transplants
Tissue Donors
Multivariate Analysis
Retrospective Studies
Confidence Intervals
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Fuji, S., Fujiwara, H., Nakano, N., Wake, A., Inoue, Y., Fukuda, T., ... Utsunomiya, A. (2016). Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplantation, 51(2), 205-211. https://doi.org/10.1038/bmt.2015.265

Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. / Fuji, S.; Fujiwara, H.; Nakano, N.; Wake, A.; Inoue, Y.; Fukuda, T.; Hidaka, M.; Moriuchi, Y.; Miyamoto, Toshihiro; Uike, N.; Taguchi, J.; Eto, T.; Tomoyose, T.; Kondo, T.; Yamanoha, A.; Ichinohe, T.; Atsuta, Y.; Utsunomiya, A.

In: Bone Marrow Transplantation, Vol. 51, No. 2, 01.02.2016, p. 205-211.

Research output: Contribution to journalArticle

Fuji, S, Fujiwara, H, Nakano, N, Wake, A, Inoue, Y, Fukuda, T, Hidaka, M, Moriuchi, Y, Miyamoto, T, Uike, N, Taguchi, J, Eto, T, Tomoyose, T, Kondo, T, Yamanoha, A, Ichinohe, T, Atsuta, Y & Utsunomiya, A 2016, 'Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma', Bone Marrow Transplantation, vol. 51, no. 2, pp. 205-211. https://doi.org/10.1038/bmt.2015.265
Fuji, S. ; Fujiwara, H. ; Nakano, N. ; Wake, A. ; Inoue, Y. ; Fukuda, T. ; Hidaka, M. ; Moriuchi, Y. ; Miyamoto, Toshihiro ; Uike, N. ; Taguchi, J. ; Eto, T. ; Tomoyose, T. ; Kondo, T. ; Yamanoha, A. ; Ichinohe, T. ; Atsuta, Y. ; Utsunomiya, A. / Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. In: Bone Marrow Transplantation. 2016 ; Vol. 51, No. 2. pp. 205-211.
@article{4869b104cde447f388794b85781334f1,
title = "Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma",
abstract = "Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, <100 days, n=72; late transplant group, ≥100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3{\%} vs 31.2{\%}). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95{\%} confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.",
author = "S. Fuji and H. Fujiwara and N. Nakano and A. Wake and Y. Inoue and T. Fukuda and M. Hidaka and Y. Moriuchi and Toshihiro Miyamoto and N. Uike and J. Taguchi and T. Eto and T. Tomoyose and T. Kondo and A. Yamanoha and T. Ichinohe and Y. Atsuta and A. Utsunomiya",
year = "2016",
month = "2",
day = "1",
doi = "10.1038/bmt.2015.265",
language = "English",
volume = "51",
pages = "205--211",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma

AU - Fuji, S.

AU - Fujiwara, H.

AU - Nakano, N.

AU - Wake, A.

AU - Inoue, Y.

AU - Fukuda, T.

AU - Hidaka, M.

AU - Moriuchi, Y.

AU - Miyamoto, Toshihiro

AU - Uike, N.

AU - Taguchi, J.

AU - Eto, T.

AU - Tomoyose, T.

AU - Kondo, T.

AU - Yamanoha, A.

AU - Ichinohe, T.

AU - Atsuta, Y.

AU - Utsunomiya, A.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, <100 days, n=72; late transplant group, ≥100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3% vs 31.2%). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.

AB - Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, <100 days, n=72; late transplant group, ≥100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3% vs 31.2%). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.

UR - http://www.scopus.com/inward/record.url?scp=84956924452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956924452&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.265

DO - 10.1038/bmt.2015.265

M3 - Article

C2 - 26524263

AN - SCOPUS:84956924452

VL - 51

SP - 205

EP - 211

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -